Literature DB >> 21150845

Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study.

Tuuli Lahti1, Jukka T Halme, Maiju Pankakoski, David Sinclair, Hannu Alho.   

Abstract

We explored the efficacy of the opiate antagonist, naltrexone, as a treatment for pathological gambling. Treatment seeking pathological gamblers (n = 39) (according to both South Oaks Gambling Screen and a screen based on the Diagnostic and Statistical Manual of Mental Disorders) participated into our treatment study during 2009. The subjects were instructed to use 50 mg of naltrexone before gambling or when feeling craving towards gambling. The protocol contained one initial doctor visit with motivational brief intervention. During period that were free of gambling, the subjects were instructed to practice other healthy behavioral alternatives to gambling. The primary outcome measure was the Yale Brown Obsessive Compulsive Scale adapted for Pathological Gambling. The other outcome measurements were the EQ-5D quality of life survey, the Alcohol Use Disorders Identification Test, and the Beck Depression Inventory. The average age of the subjects was 39 years; 80% were men. Highly significant (p < 0.01) decreases in reported obsessive-compulsive gambling and depressive symptoms and increases in the subjective quality of life developed in the study. These positive changes suggest that this simple, inexpensive treatment helps pathological gamblers. The role of naltrexone in the treatment effect, however, needs to be determined with a larger, placebo-controlled study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21150845

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  7 in total

1.  [Computer games and Internet addiction as well as pathological gambling. Therapy approaches].

Authors:  K Wölfling; T Leménager; P Peukert; A Batra
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

Review 2.  Effect of opioid antagonists on sex hormone secretion.

Authors:  H Tenhola; D Sinclair; H Alho; T Lahti
Journal:  J Endocrinol Invest       Date:  2011-12-15       Impact factor: 4.256

Review 3.  Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature.

Authors:  Shih-Ku Lin
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 4.  Pharmacological Treatments for Disordered Gambling: A Meta-analysis.

Authors:  Martina Goslar; Max Leibetseder; Hannah M Muench; Stefan G Hofmann; Anton-Rupert Laireiter
Journal:  J Gambl Stud       Date:  2019-06

5.  Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals.

Authors:  Liam J Nestor; Louise M Paterson; Anna Murphy; John McGonigle; Csaba Orban; Laurence Reed; Eleanor Taylor; Remy Flechais; Dana Smith; Edward T Bullmore; Karen D Ersche; John Suckling; Rebecca Elliott; Bill Deakin; Ilan Rabiner; Anne Lingford Hughes; Barbara J Sahakian; Trevor W Robbins; David J Nutt
Journal:  Eur J Neurosci       Date:  2018-11-26       Impact factor: 3.386

6.  Characteristics of Treatment Seeking Finnish Pathological Gamblers: Baseline Data from a Treatment Study.

Authors:  Tuuli Lahti; Jukka Halme; Maiju Pankakoski; David Sinclair; Hannu Alho
Journal:  Int J Ment Health Addict       Date:  2013-06       Impact factor: 3.836

7.  Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood.

Authors:  Waleed O Farid; Andrew J Lawrence; Elena V Krstew; Robert J Tait; Gary K Hulse; Sarah A Dunlop
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.